Invesco Biotechnology & Genome ETF (PBE)
| Assets | $256.29M |
| Expense Ratio | 0.58% |
| PE Ratio | 17.97 |
| Shares Out | 3.13M |
| Dividend (ttm) | $0.87 |
| Dividend Yield | 1.06% |
| Ex-Dividend Date | Mar 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 19.16% |
| Volume | 3,199 |
| Open | 81.75 |
| Previous Close | 81.87 |
| Day's Range | 81.29 - 81.96 |
| 52-Week Low | 58.15 |
| 52-Week High | 85.73 |
| Beta | 0.76 |
| Holdings | 33 |
| Inception Date | Jun 23, 2005 |
About PBE
Fund Home PageThe Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering. PBE was launched on Jun 23, 2005 and is issued by Invesco.
Top 10 Holdings
47.48% of assets| Name | Symbol | Weight |
|---|---|---|
| United Therapeutics Corporation | UTHR | 6.29% |
| Illumina, Inc. | ILMN | 5.54% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.95% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 4.93% |
| Incyte Corporation | INCY | 4.84% |
| Gilead Sciences, Inc. | GILD | 4.81% |
| Amgen Inc. | AMGN | 4.68% |
| Biogen Inc. | BIIB | 4.63% |
| BioCryst Pharmaceuticals, Inc. | BCRX | 3.50% |
| Protagonist Therapeutics, Inc. | PTGX | 3.32% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 23, 2026 | $0.08244 | Mar 27, 2026 |
| Dec 22, 2025 | $0.41972 | Dec 26, 2025 |
| Sep 22, 2025 | $0.23409 | Sep 26, 2025 |
| Jun 23, 2025 | $0.13047 | Jun 27, 2025 |
| Mar 24, 2025 | $0.03414 | Mar 28, 2025 |
| Jun 24, 2024 | $0.0082 | Jun 28, 2024 |
Performance
PBE had a total return of 39.74% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.74%.
News
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
2 Biotech Funds Poised for a Healthy Breakout
Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.
3 Health Care ETFs Where Components Are Enduring Downgrades
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
6 Best Biotech ETFs to Buy for Cutting-Edge Growth
Biotech ETFs are, in a word, hot.
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
Investors flee Biotech ETFs as they Lag Bull Market
Many biotech ETFs and other funds have fallen sharply off their highs in recent months.
3 Charts That Suggest Now Is the Time to Buy Into Biotech
Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.